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Introduction: S0124 is a recently completed North American phase III 
trial designed to conﬁrm the results of J9511 which previously showed 
a signiﬁcant survival beneﬁt for Cis/CPT11 over Cis/VP16 in Japanese 
patients (pts). S0124 employed the same J9511 treatment protocol. One 
hypothesis is that toxicities would differ between North American & 
Japanese pts due partly to differences in the proportion of genetic poly-
morphisms involved in chemotherapy metabolism in these populations.
Methods: Patient level toxicity data were compared among 706 pts 
enrolled in J9511 & S0124 receiving common treatment using a logis-
tic model adjusted for age, sex, and performance status (PS). Select 
polymorphisms of the UGT1A1, ABCB1, OATP, & GSTP1 genes in 
genomic DNA were evaluated in 142 pts in S0124 (67 Cis/CPT11; 75 
Cis/VP16). Associations between toxicity & genotype within each arm 
were assessed using logistic regression.
Results: Pt demographics for J9511 & S0124, respectively: Mean age - 
61 & 62 years; Male sex - 131 (86%) & 315 (57%); PS 0 - 19 (13%) & 
173 (31%); PS>0 - 133 (87%) & 372 (68%). Comparative hematologic 
toxicities (> grade 3) are summarized below. 
Cis/CPT11 Cis/VP16
J9511 
(n=75)
S0124 
(n=278)
J9511 
(n=77)
S0124 
(n=276)
Neutropenia 49 (65%)* 88 (32%) 71 (92%)* 182 (66%)
Leukopenia 20 (27%)*** 48 (17%) 41 (53%)** 92 (33%)
Anemia 21 (28%)* 16 (6%) 25 (32%)** 36 (13%)
Platelets 4 (5%) 10 (4%) 14 (18%) 42 (15%)
*P<0.0001
**P<0.01
***P=0.02
There were no signiﬁcant differences in grade 3+ non-hematologic 
toxicities between studies. Polymorphism frequencies in S0124 pts: 
ABCB1*1236 (C/C 39%; T/C 61%; T/T 0%); *3435 (C/C 31%; C/T 
46%; T/T 24%); *2627 (G/G 57%; T/G 43%; T/T 0%); UGT1A1*28 
(6/6 38%; 6/7 59%; 7/7 4%); *3156 (A/A 10%; A/G 49%; G/G 41%); 
OATP-C*521 (m/m 2%, w/m 36%, w/w 61%). ABCBq*3435 T/T was 
associated with an increased risk of CPT11 grade 3+ diarrhea (p=0.04) 
vs. C/C and C/T. UGT1A1*3156 A/A was associated with increased 
risk of CPT11 neutropenia (p=0.009) & leukopenia (p=0.05). No gene 
tested was associated with VP16 toxicity.
Conclusions: Signiﬁcant differences in treatment-related myelosup-
pression exist between J9511 and S0124 pt populations. Certain poly-
morphisms in genes involved in CPT11 metabolism are signiﬁcantly 
associated with CPT11 toxicities in S0124 pts. These results support 
the hypothesis that toxicities may be associated with distribution of 
genetic polymorphisms. Updated outcomes data from S0124 will be 
presented.
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Background: Bevacizumab’s role in the treatment of small-cell lung 
cancer is unknown. A multicenter phase II trial with bevacizumab and 
chemotherapy was conducted in patients with untreated extensive-stage 
small-cell lung cancer. 
Methods: The primary objective of this trial was to improve the histori-
cal median time to progression (TTP) of 6 months by 40%. Eligibility 
criteria included: no prior chemotherapy for small-cell lung cancer, no 
active brain metastases, normal organ function, no hemoptysis, ECOG 
PS 0-1, measurable disease, and signed informed consent. Treatment 
consisted of: irinotecan 60mg/m2 IV days 1, 8, 15, carboplatin AUC=4 IV 
day 1, and bevacizumab 10 mg/kg IV days 1 and 15 every 28 days. Re-
staging studies were performed every 2 cycles (8 weeks). If there was no 
evidence of progressive disease after 4-6 cycles of combination therapy, 
patients went on to receive maintenance bevacizumab for 6 months. 
Results: 44 pts have been enrolled from 2/06 to 3/07 (n=50 planned), 
with a median follow-up of 9 months. Baseline features included: 
median age 66 years (range 46-81); male/female, 57%/43%; 3 patients 
(7%) with previously treated brain metastases; 89% current or former 
smokers; and ECOG PS 0/1, 32%/68%. The objective response rate 
was 72% (95% CI 55%-85%), including 2 complete responses and 21 
partial responses. 7 patients (22%) had stable disease and 2 patients had 
progressive disease at restaging. 12 patients were not evaluable due to: 
comorbidity (off study), 2 patients; being too early for restaging, 10 
patients. TTP and overall survival data are not mature at the time of this 
analysis. Grade 3/4 toxicity has been limited: diarrhea (26%), fatigue 
(13%), and neutropenia (13%). There has been no signiﬁcant bleeding 
to date. 
Conclusions: Bevacizumab can be safely added to carboplatin and 
irinotecan in the ﬁrst-line treatment of extensive-stage small-cell 
lung cancer. Analysis of TTP will soon be mature to better estimate 
bevacizumab’s role in this setting. Ultimately, randomized trials will 
best assess bevacizumab’s efﬁcacy in small-cell lung cancer treatment.
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Background: Lung cancer symptoms may be very burdensome for pa-
tients with small cell lung cancer (SCLC) and may result in impairment 
in quality of life and health status. The objective of the present study 
is to compare the health status of patients treated with oral topotecan 
